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al., 2000). The cellular pathways and molecular mecha-
nisms that regulate intracellular protein misfolding and
aggregation in polyglutamine and other neurodegenera-
tive diseases remain largely unknown but might ulti-
mately be targeted to prevent neurodegeneration. Cur-
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applied to identify direct inhibitors of polyglutamine ag-4 Department of Biological Chemistry
gregation in vitro (Berthelier et al., 2001; Georgalis etUniversity of California, Irvine
al., 1998; Wanker et al., 1999). In these cases, formationIrvine, California 92697
of insoluble aggregates of purified peptides serves as5 Department of Neurology
a readout. However, these methods cannot uncover un-University of California, San Francisco
derlying mechanisms that regulate intracellular proteinSan Francisco, California 94143
misfolding. In cultured cells, two basic approaches have
been used to quantify aggregation: microscopy and de-
tergent insolubility. However, such methods are quiteSummary
labor intensive, can be prone to experimenter bias, and
are not highly quantitative. Recently Kim et al. usedMany neurodegenerative diseases, including tauopa-
fluorescence resonance energy transfer (FRET) com-thies, Parkinson’s disease, amyotrophic lateral sclero-
bined with single-cell imaging to study the constituentssis, and the polyglutamine diseases, are characterized
of large macromolecular aggregates in cultured cellsby intracellular aggregation of pathogenic proteins. It
(Kim et al., 2002). This method, while providing relativelyis difficult to study modifiers of this process in intact
precise spatial resolution, is quite time and labor inten-cells in a high-throughput and quantitative manner,
sive and does not quantify the degree of polyglutaminealthough this could facilitate molecular insights into
protein aggregation within a population of cells. More-disease pathogenesis. Here we introduce a high-
over, by focusing only on large inclusions, this and otherthroughput assay to measure intracellular polygluta-
microscopy-based approaches ignore small oligomericmine protein aggregation using fluorescence reso-
microaggregates that may play an important role innance energy transfer (FRET). We screened over 2800
pathogenesis (Taylor et al., 2003). To overcome the limi-biologically active small molecules for inhibitory activ-
tations of current technology, we have developed a high-ity and have characterized one lead compound in de-
throughput assay based on FRET that allows quantita-tail. Y-27632, an inhibitor of the Rho-associated kinase
tive measurement of polyglutamine protein aggregationp160ROCK, diminished polyglutamine protein aggre-
within cultured cell monolayers and provides a novelgation (EC50  5 M) and reduced neurodegeneration
approach to study the cell biology of polyglutaminein a Drosophila model of polyglutamine disease. This
expansion diseases.establishes a novel high-throughput approach to study
Polyglutamine diseases derive from CAG-codon expan-protein misfolding and aggregation associated with
sion in certain genes. This enlarges a tract of glutaminesneurodegenerative diseases and implicates a signal-
in the target protein that produces neurodegenerationing pathway of previously unrecognized importance
when it exceeds a critical threshold. Spinobulbar mus-in polyglutamine protein processing.
cular atrophy (SBMA) is a progressive motor neuron
disease caused by polyglutamine expansion in the N
Introduction terminus of the androgen receptor (AR) (Kennedy et al.,
1968; La Spada et al., 1991); Huntington’s disease (HD) is
Human neurodegenerative disorders such as the tauo- a progressive neuropsychiatric degenerative condition
pathies (including Alzheimer’s disease), Parkinson’s dis- with an associated movement disorder and derives from
ease, amyotrophic lateral sclerosis, and polyglutamine a similar expansion in a protein of unknown function,
expansion diseases are all characterized by misfolding huntingtin (htt) (Huntington Collaborative, 1993). Cellular
and intracellular aggregation of pathogenic proteins. toxicity in most diseases correlates with nuclear accu-
These phenomena appear closely linked to pathology, mulation and inclusion formation of mutant protein and,
although it remains uncertain whether they represent a in certain cases, may derive from “toxic fragments” pro-
step in pathogenesis or even a protective mechanism. duced through proteolysis (DiFiglia et al., 1997; Ellerby
It is clear, however, that polyglutamine misfolding and et al., 1999; Hodgson et al., 1999; Li et al., 1998; Merry
aggregation occurs in a controlled fashion: it is noted et al., 1998).
primarily in affected neurons in patients and is subject Several lines of evidence suggest that cells form inclu-
to regulation within the cell by various pathways (Chen sions as a physiological response to pathogenic pro-
et al., 2003; Diamond et al., 2000; Emamian et al., 2003; teins, although it remains unclear whether this is a pro-
Humbert et al., 2002; Meriin et al., 2001; Wyttenbach et tective or harmful process. Neurons of the central
nervous system predominantly form nuclear inclusions,
especially in affected regions, whereas somatic tissues*Correspondence: marcd@itsa.ucsf.edu
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generally do not (DiFiglia et al., 1997; Li et al., 1998; emission before and after photobleaching YFP, using
digital photography to record fluorescence intensities.Paulson et al., 1997). Activation of stress pathways via
heat shock or JNK activation increases polyglutamine Photobleaching increased CFP emission from either cy-
toplasmic or nuclear inclusions an average of20% butprotein aggregation (Cowan et al., 2003; Meriin et al.,
2001; Wyttenbach et al., 2000). In response to activation not from diffusely distributed protein (Figures 1G–1L).
In cells expressing unexpanded protein there was noof Akt kinase, one group has reported decreased htt
toxicity and aggregation in cell models (Humbert et al., aggregation, and no FRET signal was detected. We also
obtained similar results in HEK293 cells (data not2002), while others report increased ataxin-1 toxicity and
aggregation (Chen et al., 2003). Several reports indicate shown). To confirm that polyglutamine aggregates
would produce FRET in neural cells, we employed differ-that cytoplasmic inclusion formation within cells is a
microtubule-dependent process (Garcia-Mata et al., entiated C17-2 neural precursor cells (Figures 1C–1F;
Snyder et al., 1992). In this case, we measured FRET1999; Muchowski et al., 2002; Taylor et al., 2003). Last,
our prior work has demonstrated that overexpressed according to a three filter-set method, which corrects
for CFP bleedthrough into the YFP emission spectrumwild-type glucocorticoid receptor (GR) diminishes poly-
glutamine protein aggregation after activation by hor- and crossover activation of YFP by CFP excitation
(Schaufele et al., 2003; Weatherman et al., 2002). Wemone agonist, whereas a mutant form (GR) increases
nuclear inclusion formation and polyglutamine-depen- measured FRET in cells with nuclear aggregates versus
those with diffuse distribution of protein. Whereas dif-dent toxicity (Diamond et al., 2000; Welch and Diamond,
2001). Thus, polyglutamine protein conversion from a fusely distributed protein produced no significant FRET
signal (FRET/CFP 0.023 .041, n 8), nuclear aggre-soluble to an aggregated form appears to be a highly
regulated process within the cellular milieu and is not gates had clear FRET signal (FRET/CFP  0.176  .78,
n  19). Thus, by separate methods in neural and non-driven simply by a propensity for self-association. To
identify mechanisms that would not have been clearly neural cells, both nuclear and cytoplasmic inclusions
produced strong FRET, whereas diffusely distributedpredicted from prior knowledge, we chose to investigate
the cellular regulation of aggregate formation using a protein did not.
high-throughput approach. Here we describe the devel-
opment of this method, its use as a screening tool to Detection of FRET Signal in Cell Monolayers
identify a potential therapeutic compound, and new in- Using Emission Scans in a Fluorescence
sights into a pathway that can regulate polyglutamine Plate Reader
aggregation. To monitor polyglutamine protein aggregation based
on FRET in transfected cell monolayers, we created an
assay system using a monochrometer-based fluores-Results
cence plate reader (FPR). We used HEK293 cells for
their ease of transfection and high protein expressionAggregated Polyglutamine Proteins Produce
FRET when Fused to Fluorescent Proteins levels and our ability to induce a high degree of nuclear
aggregation. We performed emission scans using exci-To develop a screening assay, we began with an amino-
terminal 127 amino acid fragment of AR containing either tation at either 435 nm or 485 nm, and controls of CFP
and YFP alone to calculate CFP bleedthrough into the25 glutamine repeats (ARN127(25)) or a pathologic ex-
panded tract of 65 repeats (ARN127(65)). These poly- YFP spectrum, and crossover activation of YFP by 435
nm excitation. These scans detected a robust FRETpeptides were fused at their carboxyl termini either to
CFP or YFP coding sequences (Figure 1A). Similar trun- signal from cells expressing a positive control YFP-CFP
fusion protein (Figure 2A). Co-expression of individualcated AR gene products have previously been shown to
reproduce a neurodegenerative phenotype in transgenic CFP and YFP proteins produced no FRET, despite their
colocalization as assayed by fluorescence microscopyanimals and cell models (Abel et al., 2001; Merry et
al., 1998; Welch and Diamond, 2001). When expressed (data not shown). To characterize the system, we moni-
tored changes in polyglutamine protein aggregation fol-transiently in mammalian cells, the unexpanded forms
of the protein (ARN127(25)CFP/YFP) remained diffusely lowing dexamethasone (dex) activation of co-expressed
GR or GR, as described previously by us: GR reducesdistributed throughout the cytoplasm (data not shown).
In contrast, the expanded proteins (ARN127(65)CFP/ AR and htt aggregation, whereas GR increases nuclear
aggregate formation and cell toxicity (Figure 1B; Dia-YFP) spontaneously formed perinuclear or nuclear ag-
gregates (Figure 1). mond et al., 2000; Welch and Diamond, 2001). We ob-
served a highly specific and reproducible correlationWe measured FRET initially in transfected nonneural
and neural cells by two distinct microscopy-based between FRET signal and polyglutamine protein aggre-
gation. Emission scans on the FPR demonstrated amethods. First, photobleaching was used to test
whether aggregate-containing cells could be distin- small FRET signal for ARN127(25)CFP/YFP that was not
significantly modulated by dex (Figure 2B). By contrast,guished from those with soluble protein based on differ-
ences in their FRET signals. When FRET occurs, photo- ARN127(65)CFP/YFP produced relatively strong FRET
signals that were modulated as expected upon activa-bleaching the acceptor (YFP) molecule increases donor
(CFP) emission. For ease in imaging, we transfected tion of GR (to reduce aggregation) or GR (to increase
aggregation) (Figure 2C). These were approximatelyCOS-7 cells with ARN127(65)CFP/YFP and GR to cre-
ate a population of cells with diffuse protein or either 10%–20% of the signal strength from the YFP-CFP fu-
sion. The intensity of the FRET signal correlated wellcytoplasmic or nuclear aggregates. We examined indi-
vidual cells under a microscope and quantified CFP with measures of aggregate formation made by direct
Aggregation Assay Reveals a Novel Inhibitor
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Figure 1. FRET Efficiencies of Soluble and
Aggregated Forms of Fluorescently Labeled
AR
(A and B) Diagrams of AR and GR constructs.
(A) The full-length AR is shown for reference.
Truncated forms contained the first 127
amino acids of AR (ARN127(Qn)) with either
an unexpanded (n  25) or expanded (n 
65) tract of glutamines. The truncated forms
were fused to coding sequences of cyan and
yellow fluorescent proteins (CFP and YFP, re-
spectively). (B) Full-length GR and GR,
which carries a deletion of an activation do-
main, amino acids 108–317. The constitutive
RSV promoter drove expression of each pro-
tein. DBD  DNA binding domain. LBD  li-
gand binding domain.
(C–F) Representative nuclear aggregates and
diffuse distribution of ARN127(65)CFP/YFP in
differentiated C17-2 neural cells used for
measurement of FRET. Green signal repre-
sents polyglutamine protein; red represents
a neuronal marker (neural tubulin) induced
upon differentiation. Nuclei are counter-
stained with DAPI. Panels (C) and (D) show
ARN127(65)CFP/YFP in diffuse distribution, with tubulin stain included in (D). Yellow color in (D) reflects superimposition of red and green
signals. Panels (E) and (F) demonstrate nuclear aggregates, with tubulin stain included in (F). FRET was calculated in transfected cells using
three filter-set measurements, with FRET/CFP ratios of .023  .041 (SD) for diffuse protein (n  8), signifying no significant FRET, versus
0.176  0.78 (SD) for nuclear aggregates (n  19), signifying FRET.
(G–L) Images of diffuse and aggregated forms of AR and their qualitative FRET efficiencies in COS-7 cells. ARN127(65)CFP/YFP were co-
expressed with GR by transient transfection and cultured in the presence of 100 nM dex. Cells were fixed on coverslips and stained with
DAPI. (G), (H), and (I) are standard fluorescence images taken on three channels (CFP, YFP, DAPI) and superimposed. Yellow results from
colocalization of CFP and YFP. Images show the three characteristic polyglutamine protein distribution patterns: (G) diffuse, (H) cytoplasmic
inclusion, and (I) nuclear inclusions. (J), (K), and (L) are calculated images that show the distribution of FRET efficiencies in the cells shown
in (G), (H), and (I) based on applying the following formula to each pixel of the image: (CFPf  CFPi)/CFPf, where CFPi and CFPf are the CFP
intensities before and after photobleaching of YFP, respectively. The resulting calculated grayscale image was converted to color-scale using
NIH-Image software. Note that diffuse protein had no significant increase in CFP signal following photobleaching, whereas both nuclear and
perinuclear aggregates had increased CFP signal, indicating FRET.
observation with fluorescence microscopy (data not this case aggregated versus nonaggregated polyglu-
tamine protein); values 0.5 represent a highly robustshown) and by detergent fractionation (Figure 2D).
system.
Development of a High-Throughput FRET-Based
Assay of Protein Aggregation High-Throughput Screening for Inhibitors
of Polyglutamine AggregationTo create a high-throughput system, we replaced the
two emission scans with three individual measurements Prior to embarking on a large-scale screen, we began by
testing a small number of well-characterized biologicallyusing the following excitation/emission windows: CFP
(435 nm ex/485 nm em), YFP (485 nm ex/530 nm em), active small molecules chosen on the basis of potential
effects on polyglutamine protein aggregation and celland FRET (435 nm ex/530 nm em). This provided a quan-
titative measure of polyglutamine protein aggregation signaling. We cotransfected HEK293 cells with ARN127
(65)CFP/YFP and dex-activated GR to maximize nuclearwith no loss of fidelity (Figure 2E). Dose-response titra-
tions of dex using either GR (to reduce aggregation) or aggregate formation and cultured them in the presence
of the compounds. FRET measurements were takenGR (to increase aggregation) demonstrated the accu-
racy of this system, allowing rederivation of the Kd of after 48 hr. To our surprise, one compound, Y-27632,
decreased FRET by 40%, without concomitant loss ofdex for GR and GR (1 nM) using FRET as a readout
(Figure 2F). Thus, this detection method allows rapid CFP or YFP signal (Figures 3A and 3B). Y-27632 is a
well-characterized inhibitor of the Rho-activated serine/and quantitative analysis of polyglutamine protein ag-
gregation in a 96-well format. We confirmed the suitabil- threonine kinase, p160ROCK (Ishizaki et al., 2000; Naru-
miya et al., 2000). A dose-response analysis demon-ity of this system for high-throughput screening by cal-
culating the Z value to be 0.67 according to the formula strated an EC50 of approximately 5 M for the effect of
Y-27632 on polyglutamine aggregation (Figure 3C). This1  (3x  3y)/|x  y|, where x and y represent
the standard deviation of positive and negative signals, is consistent with the EC50 of Y-27632 in modulation of
stress-fiber formation via inhibition of p160ROCK (Ish-respectively, and x and y represent the average value
of the positive and negative signals, respectively (Zhang izaki et al., 2000). Direct visualization (data not shown)
and detergent fractionation confirmed our FPR findingset al., 2000). This number reflects the ability of a screen
to distinguish two distinct signals, taking into consider- (Figure 3D). Y-27632 also inhibited aggregation of htt
exon 1-CFP and -YFP fusions containing 72 repeatsation the mean value and standard deviation of each (in
Neuron
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Figure 2. Detection of Polyglutamine Protein Aggregation in Cell Monolayers Using a Fluorescence Plate Reader
HEK293 cells were transfected with (A) YFP-CFP fusion, (B) ARN127(25)CFP/YFP plus GR or GR, or (C) ARN127(65)CFP/YFP plus GR or
GR and cultured in a 96-well dish for 48 hr. GR and GR mediate down- or upregulation, respectively, of polyglutamine protein aggregation
when cultured with 100 nM dex.
(A–C) Emission peaks with maxima near 527 nm (YFP emission maximum) indicate FRET. (A) The YFP-CFP fusion produced a robust FRET
signal. (B) The unexpanded AR127(25)CFP/YFP proteins produced a small FRET signal that was not significantly modulated by GR or GR
activation. (C) The expanded AR127(65)CFP/YFP proteins produced strong FRET signals in absence of dex (blue and green curves), which
were diminished by activated GR (pink) and increased by activated GR (red). Note the scale differences on the y axes.
(D) HEK293 cells were transfected with ARN127(25)YFP or ARN127(65)YFP along with GR or GR. After culture for 48 hr with or without 100
nM dex, cells were lysed in 1% Triton/PBS. Following centrifugation at 15,000 	 g, proportional amounts of SDS-denatured supernatant
(SUPE) and pellet (PELLET) fractions were resolved by SDS-PAGE and immunoblotted with anti-AR antibody. Band intensities were determined
by densitometry. AR127(25)YFP did not produce significant amounts of detergent-insoluble material. AR127(65)YFP expression resulted in
significant amounts of detergent-insoluble material that was decreased by GR and increased by GR following addition of dex.
(E) The same wells from (B) and (C) analyzed using excitation/emission windows on the FPR quantitatively reflect results from the emission
scans. Error bars represent SEM.
(F) The Kd of dex for GR and GR is accurately rederived via the FRET-based assay of aggregation. HEK293 cells were transfected with
AR127(65)CFP/YFP and GR or GR, and were treated with increasing amounts of dex. GR decreased and GR increased FRET signals, with
an EC50 of dex (1 nM) that reflects the known Kd of dex for GR. Curves were plotted as fractional signals with minimum signal arbitrarily set
to zero and maximum set to 100.
(htt(72)CFP/YFP) (Figure 3B), demonstrating that its ef- most had negligible effects on polyglutamine aggrega-
tion (0%–30% reduction), attributable primarily to well-fects were not limited to a single polyglutamine protein.
Next, we tested this method as a high-throughput well variation in the assay. In contrast, a small number
of compounds showed more robust effects of 50%system by initiating a screen of 2800 biologically active
compounds, comprising the Annotated Compound Li- reduction in aggregation (Figure 3E). Detailed secondary
screens will be required to characterize these hits; how-brary (ACL) (Root et al., 2003). This required small adap-
tations of our protocol to include internal controls and ever, these results demonstrate the power of this
screening method to identify inhibitors across a broadinterassay standardization. Polyglutamine aggregation
may be reduced by several means, including decreased spectrum of compounds.
protein expression, increased protein turnover, and mo-
lecular interactions within the cell that modify the pro- Genetic Analysis of Pathways Implicated
by Y-27632pensity for misfolding. To control for the first two possi-
bilities, we created an HEK293 cell line with stable Although we identified a number of potential inhibitors
from our large-scale screen, we chose to study furtherexpression of monomeric red fluorescent protein (mRFP),
which allowed elimination of compounds that nonspe- the effects of Y-27632. Thus, we tested whether a domi-
nant-negative mutant of the putative target, p160ROCK(KD-cifically decreased steady-state protein levels. Likewise,
to ensure accurate comparison of compounds across IA), would also attenuate polyglutamine protein aggrega-
tion (Hirose et al., 1998; Ishizaki et al., 1997). Comparedmultiple experiments, we included on each plate a “no
aggregation” control of unexpanded ARN127(25)CFP/ to empty expression vector, p160ROCK(KD-IA) de-
creased ARN127(65)CFP/YFP aggregation by 20%YFP. For an individual experiment, each compound’s
activity was thus scaled between a 0% and 100% effect. (Figure 4A). While modest, these results were consistent
with the pharmacologic effects of Y-27632 and raisedCompounds were assayed in duplicate. We found that
Aggregation Assay Reveals a Novel Inhibitor
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Figure 3. Y-27632, an Inhibitor of
p160ROCK, Prevents Polyglutamine Protein
Aggregation; Results of a High-Throughput
Screen for Inhibitors of Aggregation
(A) Chemical structure of Y-27632.
(B) Y-27632 inhibits polyglutamine protein ag-
gregation in the nucleus and cytoplasm.
HEK293 cells were transfected with
ARN127(65)CFP/YFP without and with GR
to produce cytoplasmic or nuclear inclusions,
or htt(72)CFP/YFP alone, and cultured in the
presence or absence of 50 M Y-27632 for
48 hr. FRET intensity of ARN127(65)CFP/YFP
in the absence of co-expressed GR is set
arbitrarily to 1. “Cyto” and “nuc” refer to the
predominant location of inclusions in each
condition (cytoplasmic versus nuclear). Error
bars represent the SEM. All pair-wise analy-
ses are significant to at least p 
 .001 by
ANOVA.
(C) Y-27632 inhibited aggregation of
ARN127(65)CFP/YFP with an EC50 of approxi-
mately 5 M. Fractional FRET signals were
plotted with minimum signal arbitrarily set to
zero and maximum set to 100.
(D) Titration of Y-27632 with detergent fractionation confirmed the effect of Y-27632 on ARN127(65)CFP/YFP aggregation. HEK293 cells were
transfected with ARN127(65)CFP/YFP and treated with the indicated amounts of Y-27632 for 48 hr. Detergent fractionation was followed by
Western blot, which indicated that Y-27632 reduced ARN127(65)CFP/YFP detergent insolubility in a dose-dependent manner.
(E) Summary results from the Annotated Compound Library screen. The histogram reflects the total number of compounds in each activity range.
the possibility that p160ROCK signaling might be in- uncertain the precise mechanism by which Y-27632
functions but strongly implicates pathways that regulatevolved in polyglutamine aggregation.
p160ROCK is best known as an effector of RhoA but the cytoskeleton in the control of polyglutamine aggre-
gation.may also be controlled by other rho-GTPases, including
Rac, to regulate cytoskeletal dynamics. In fact, in cells
treated with Y-27632, we noticed cytoskeletal changes: Analysis of Y-27632 in a Drosophila Model
of Neurodegenerationcells extended longer processes and appeared to
spread out farther on the culture dish (data not shown). Finally, we tested whether Y-27632 might have a thera-
peutic effect in a Drosophila model of polyglutamineTo determine which GTPase might exert an effect on
polyglutamine protein aggregation, we co-expressed neurodegenerative disease. In this model, a htt exon 1
fragment containing an expanded tract of 93 glutaminesconstitutively active or dominant-negative mutants of
RhoA, Rac1, and Cdc42 with ARN127(65)CFP/YFP and (htt exon1(Q93)) is expressed in all neurons under the
control of the elav:Gal4 driver system. Photoreceptorcompared their effects to empty vector (pcDNA3). Domi-
nant-positive and -negative RhoA and Cdc42 mutants neurons are easily observed as seven light-transmitting
rhabdomeres within each ommatidium of the Drosophilaeach increased polyglutamine aggregation to varying
degrees (data not shown). On the other hand, dominant- compound eye. Expression of htt exon1 (Q93) causes
progressive neurodegeneration of photoreceptor neu-negative N17Rac1 suppressed aggregation 20%,
while its dominant-positive counterpart, V12Rac1, in- rons, as demonstrated by reduction in the number of
rhabdomeres present in each ommatidium (Steffan etcreased polyglutamine aggregation 40% (Figure 4B).
These experiments implicated the rho-GTPase family, al., 2001). Following eclosion, adult flies expressing the
transgene were grown for 7 days in the presence orand Rac1 in particular, as potential regulators of polyglu-
tamine aggregation. absence of 25 M Y-27632 in their food. Drug treatment
slowed the loss of photoreceptor neurons, as revealedWe further tested the role of Rac1 in this process
by comparing two dominant-positive V12Rac1 mutants by an increase in the average number of rhabdomeres
per ommatidium, preventing 29% of the rhabdomerecontaining additional single amino acid substitutions in
their effector loop domains. F37A selectively interferes loss induced by polyglutamine protein overexpression
(Figures 4C and 4D). Thus, in addition to reducing poly-with Rac1’s interaction with p160ROCK, blocking regu-
lation of lamellipodia formation while leaving intact its glutamine aggregation in mammalian cells, Y-27632 is
neuroprotective in this Drosophila model of polygluta-regulation of the JNK pathway. In contrast, Y40C has
no effect on p160ROCK interaction but blocks JNK acti- mine protein toxicity.
vation (Lamarche et al., 1996). The F37A mutation in
V12Rac1 diminished its upregulation of aggregation, Discussion
whereas the Y40C mutation did not (Figure 4B). Thus,
Rac1 interaction with p160ROCK, or a structurally re- In this work we have developed a quantitative, high-
throughput FRET-based assay of polyglutamine aggre-lated protein, appears crucial to its regulation of polyglu-
tamine aggregation. Taken together, this data leaves gation in mammalian cell monolayers, demonstrated its
Neuron
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limited number of compounds and identified Y-27632
as an inhibitor of polyglutamine protein aggregation. We
investigated the pathway implicated by Y-27632 and
tested the efficacy of this compound in a Drosophila
model of polyglutamine disease. Y-27632 is described
as an inhibitor of the Rho-activated serine/threonine ki-
nase p160ROCK, but like most kinase inhibitors, it can
have off-target activities. We approximated its effect by
overexpressing a dominant-negative p160ROCK mu-
tant, p160ROCK(KD-IA). When we assayed potential up-
stream regulators of p160ROCK—RhoA, Rac1, and
Cdc42—we found that a dominant-positive Rac1 mutant
increased polyglutamine protein aggregation, whereas
a dominant-negative mutant inhibited this process. Fur-
thermore, a mutation in Rac1 that blocks its interaction
with p160ROCK also reduced the effects of Rac1 on
polyglutamine aggregation.
The interpretation of the effects of dominant-positive
and -negative Rho, Rac, and Cdc42 mutants in this regu-
latory system is complex, however. There is significant
cross-talk between these pathways, and one rho-
GTPase may modulate the activity of another (Etienne-
Manneville and Hall, 2002; Hirose et al., 1998). Although
the effects of the Rac1 mutants do not present a clear
mechanistic interpretation, together with Y-27632 they
imply a significant role of the cytoskeleton in the regula-
Figure 4. The Rac Pathway Regulates Polyglutamine Protein Aggre- tion of aggregation. Based on imaging of the microtu-
gation; Y-27632 Functions in Drosophila to Reduce Polyglutamine- bule network in the presence and absence of Y-27632
Dependent Neurodegeneration
(J.S., unpublished data), we believe that this mechanism
(A and B) HEK293 cells were cotransfected with AR127(65)CFP/
is distinct from previously reported microtubule-depen-YFP and the indicated plasmids and assayed after 48 hr in culture.
dent effects on aggregation (Johnston et al., 1998; Mu-p160ROCK and Rac1 mutants were expressed from a pcDNA3 vec-
chowski et al., 2002; Taylor et al., 2003). On the othertor. Histograms show FRET values relative to cells cotransfected
with AR127(65)CFP/YFP and empty vector (pcDNA3). (A) Co-expres- hand, our results provide an alternative interpretation
sion of p160ROCK(KD-IA) reduced aggregation of AR127(65)CFP/ to the work of Peters et al., implying that arfaptin 2/POR1
YFP by 20% (p 
 .0001 by ANOVA). (B) Overexpression of domi- (partner of Rac1) might regulate htt aggregation via influ-
nant-positive V12Rac increased aggregation, whereas overexpres- ence on Rac1 signaling, rather than proteasome inhibi-
sion of dominant-negative N17Rac decreased polyglutamine aggre-
tion (Peters et al., 2002).gation. Presence of the F37A mutation (which inhibits Rac1 binding
Several features of the current approach should beto p160ROCK) reduced the activity of V12Rac, whereas the Y40C
noted. By design it is not an assay of cell death ormutation (which does not affect Rac1 binding to p160ROCK) did
not reduce V12Rac activity. dysfunction and is limited to detection of modifiers of
(C and D) Expanded polyglutamine htt exon 1(Q93) protein was protein folding and aggregation. Secondary screens in
expressed in Drosophila neurons, which results in loss of the normal Drosophila and cell models may be used determine
number of seven visible rhabdomeres within each ommatidium. whether candidate compounds have efficacy against
Adult flies were grown in the presence or absence of 25 M
cell dysfunction and death. In anticipation of possibleY-27632, and rhabdomeres were counted at seven days. (C) Y-27632
arrayed cDNA library screens, which require high trans-increased the percentage of ommatidia with six or seven rhabdo-
fection efficiency and robust protein expression, themeres, with a corresponding decrease in the number of those with
two, three, or four. (D) Analysis by average number of rhabdomeres/ assay used here employed transfected nonneural cells
ommatidium per fly demonstrated a significant reduction in rhab- (HEK293). Preliminary data from C17-2 neural cells, how-
domere loss at 7 days, representing a 29% reduction in degeneration ever, shows that polyglutamine aggregates may be de-
(p 
 .0003 by ANOVA). tected via FRET, and in the future, use of stable neural
cell lines expressing the CFP and YFP fusion proteins
might increase detection of pathways relevant in vivo.
utility as a high-throughput screening tool, and charac- Nonetheless, employing nonneural cells to study basic
terized in detail one lead compound. The use of FRET mechanisms associated with protein misfolding and ag-
to study heterologous protein-protein interactions has gregation, this assay identified a compound beneficial
been widely reported, even for polyglutamine proteins within the Drosophila nervous system.
(Kim et al., 2002; Sekar and Periasamy, 2003). To our Advantages of this approach are numerous. Because
knowledge, however, this is the first use of such technol- the assay depends on particular molecular events—
ogy to study intracellular protein interactions on a quan- misfolding and aggregation—it is likely that hits will be
titative, high-throughput basis, entirely distinct from mi- relatively specific to this process. In contrast to micros-
croscopy. We demonstrated the ability of this approach copy-based methods that rely on analysis of macromo-
to quantitatively and rapidly screen the ACL (approxi- lecular aggregation, this FRET-based method in theory
mately 2800 compounds) and are currently analyzing the will produce signal even if aggregates consist of oligo-
meric structures that escape standard detection. Sec-candidates. In an initial screen, however, we examined a
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Cell Culture and Transfectionond, because the assay is cell based, it has clear advan-
For photobleaching experiments, COS-7 cells were transfected ontages over in vitro assays of protein aggregation, which
coverslips in 6-well dishes. Each well was transfected with 1 g ofare only capable of identifying direct modifiers of the
a mixture of AR127(65)CFP/YFP and 1 g GR using 10 l Plus and
protein of interest. Small molecules that directly target 12 l Lipofectamine according to manufacturer’s protocol (In-
polyglutamine proteins will also score in this assay, but vitrogen). After 5 hr, transfection medium was replaced with com-
plete medium containing 100 nM dex, and cells were cultured for 48so will molecules such as Y-27632, which modulate mis-
hr to allow aggregate formation. For experiments in the fluorescencefolding and aggregation indirectly through action on reg-
plate reader, high-throughput screening, and detergent fraction-ulatory pathways. We have comparatively little knowl-
ation, HEK293 cells in 6-well plates were transfected with a total ofedge about the intracellular regulation of protein folding
2 g of DNA using 10 l Plus and 12 l Lipofectamine according
that underlies numerous neurodegenerative diseases. to manufacturer’s protocol. To control for autofluorescence and
Although this method was applied here to polyglutamine light scattering by mammalian cells, a control group was transfected
with 2 g pcDNA3. To control for bleedthrough and crossover exci-proteins, it should also be amenable to study the regula-
tation, CFP and YFP controls were transfected with 1 g pECFP-tion of folding of other aggregation-prone molecules
C1 (Clontech) and 1 g pcDNA3 (Invitrogen) or 1 g pEYFP-C1responsible for neurodegenerative disease, such as tau,
(Clontech) and 1 g pcDNA3, respectively. After 5 hr, cells weresynuclein, superoxide dismutase, and prion protein.
counted and plated into optically clear 96-well plates (Costar 3603)
Taken together, this work has contributed three ele- at a density of 60,000 cells/well. For assays of p160ROCK(KD-IA),
ments to the study of polyglutamine disease. The FRET- it was necessary to reduce the amount of this plasmid by 80% due
to toxicity at higher levels: 0.2g p160ROCK(KD-IA), 0.8g pcDNA3,based assay system offers a new approach to identify
and 1 g of either 6RARN127(65)CFP/YFP or 6Rhtt(72)CFP/YFPregulatory mechanisms that control protein misfolding
were used. For assays of rho-GTPase mutants, 1 g of each wasand aggregation, possibly in multiple diseases. It com-
used in conjunction with 1 g of the polyglutamine expression plas-plements existing strategies by creating opportunities
mids. Transfections were performed in triplicate, and each experi-
to screen chemical and genetic libraries in a high- ment was repeated 6 times. C17-2 neural precursor cells were plated
throughput format in the context of intact mammalian in 12-well plates and transfected using 4 g of DNA and 4 l of
Lipofectamine 2000. 16 hr following transfection, cells were replatedcells. This method might also be extended in the future
on coverslips coated with poly-L-lysine and laminin and grown into study libraries of arrayed cDNAs or siRNAs. Second,
DME-H21 supplemented with 1% fetal bovine serum and 100 ng/mlthis work has identified regulatory pathways that impli-
each of NGF and mitomycin for 2 days. Polyglutamine protein wascate regulation of the cytoskeleton in the control of po-
visualized by direct fluorescence; neuron-specific tubulin was visu-
lyglutamine misfolding, aggregation, and toxicity. Last, alized by immunostaining with mouse monoclonal antibody Neuro
the identification of Y-27632 as an inhibitor of polyglu- TUJ1 (Covance) at 1:1000.
tamine protein aggregation in mammalian cells and of
Detection of FRET via Photobleaching of Fixed Cellsneurodegeneration in Drosophila may provide an impor-
Fixed COS-7 cells on coverslips were mounted in 50% glycerol/tant lead in the development of treatments for patients.
PBS without bleach retardant 48 hr after transfection. All imagesFurther study of the potential therapeutic value of
were obtained using a 60	 1.4 N.A. lens (Olympus, Lake Success,
Y-27632 and modulation of cytoskeletal regulatory path- NY) and N  1.518 immersion oil. Digital images were acquired
ways in fly, worm, and mouse models of polyglutamine using a 12-bit cooled charge-coupled device on a multiwavelength
wide-field optical sectioning microscopy system (Deltavision, Ap-disease should be very informative.
plied Precision, Issaquah, WA). Channels used for imaging were as
follows: CFP: exciter D436/10, JP4 beamsplitter, emitter D470/30;
Experimental Procedures YFP: exciter HQ500/14, JP4 beamsplitter, emitter HQ535/30 (Chroma
Technology Corp., Brattleboro, VT). To create an image in which
Plasmid Construction the intensity reflected an estimate of FRET efficiency, on a pixel-
To construct ARN127-CFP and ARN127-YFP fusion proteins, coding by-pixel basis the value of the initial CFP image was subtracted
sequences for ECFP and EYFP were PCR amplified from pECFP.C1 from the final CFP image obtained after photobleaching, and this
and pEYFP.C1 (Clontech) and were cloned downstream of ARN127 difference was multiplied by 100 and divided by the final CFP image
sequence into p6RARN127 (Diamond et al., 2000) to form intensity: 100	(CFPfinalCFPinitial)/CFPfinal. Image arithmetic was per-
p6RARN127(Qn)CFP or p6RARN127(Qn)YFP, with Q 25 or 65 CAG formed using Deltavision software and converted from grayscale to
repeats. To construct the YFP-CFP fusion protein, an intermediate color using NIH-Image 1.62 software.
vector was constructed in which the HincII/BsrGI fragment of pEYFP
(Clontech) containing the coding region for YFP was placed into the Detection of FRET via Three Filter-Set Measurements
Eco47III/BsrGI backbone of pEGFP-C1 (Clontech) to excise EGFP For FRET detection in C17-2 cells via three filter-set measurements,
and create a vector with polylinkers on both 3 and 5 sides of the fixed cells on coverslips were analyzed by direct fluorescence mi-
EYFP coding region. Then the BamHI fragment of this vector was croscopy. All images were collected using an Olympus 60	 Plan
subcloned into the BamHI/BglII backbone on ECFP-N3 to place Apochromat objective and quantitative fluorescence microscopy
EYFP in-frame and 5 to ECFP. To construct htt exon 1-CFP and equipment as previously described (Schaufele et al., 2003; Weather-
-YFP fusions, htt exon 1 fragment derived from plasmid qp72 (a man et al., 2002). For each cell, three fluorescence channels were
gift from A. Kazantsev) was subcloned as a SalI/BamHI fragment, collected: the donor channel consisted of CFP excited with 431–440
replacing the ARN127 coding sequence in p6RARN127CFP/YFP to nm light and CFP fluorescence collected at 455–485 nm, the ac-
form p6Rhtt(72)CFP and p6Rhtt(72)YFP. Plasmid encoding p160ROCK ceptor channel consisted of YFP excited with 496–505 nm light and
(KD-IA) was kindly provided by S. Narumiya. Plasmids encoding YFP fluorescence collected at 520–550 nm, and the FRET channel
dominant-positive and -negative rho-GTPase mutants (RhoA, Rac1, consisted of CFP excited with 431–440 nm light and YFP fluores-
Cdc42) were obtained from the cDNA Resource Center at the Guthrie cence collected at 520–550 nm. Cells separately expressing
Research Institute (http://www.guthrie.org). F37A and Y40C muta- ARN127(65)CFP and ARN127(65)YFP were used to determine the
tions in V12Rac were introduced by site-directed mutagenesis using separate contributions of the donor and acceptor fluorophores to
QuickChange (Stratagene) and the following primers: F37A, GGA each channel for both diffuse and aggregated protein.
GAATATATCCCTACTGTCGCTGACAATTATTCTGCC (plus strand),
GGCAGAATAATTGTCAGCGACAGTAGGGATATATTCTCC (minus Emission Scans on the Fluorescence Plate Reader
strand); Y40C, GTCTTTGACAATTGTTCTGCCAATG (plus strand), After 48 hr in culture, cells were fixed for 2 min in 10% formaldehyde/
PBS, the formaldehyde was replaced with 200 l per well of PBS,CATTGGCAGAACAATTGTCAAAGAC (minus strand).
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and the cells were read on a fluorescence plate reader (SAFIRE, 1:2000 dilution (Santa Cruz Biotechnology). Following secondary
antibody incubation, blots were developed using chemiluminescentTecan, Inc.). Automated scans were performed in which each well
was excited at 435  2.5 nm while monitoring emission from 455  substrate and exposure to X-ray film. Densitometry scans were
performed on the film using NIH Image 1.62 software. These experi-6 nm to 600  6 nm (FRET scan) to record CFP and FRET signals
and then excited at 485  2.5 nm while monitoring emission from ments were repeated at least six times with similar results.
500  6 nm to 600  6 nm (YFP scan) to record YFP signal. Data
were analyzed as follows. First, the averaged signals from wells Limited Chemical Screen
transfected with vector alone were used to background subtract all HEK293 cells were transfected and replated in 96-well plates. Test
other signals. To normalize for CFP expression, a control sample wells were transfected with ARN127(65)CFP/YFP and GR. Cells
transfected with CFP alone was used. Sample 435 nm and 485 nm were cultured with 100 nM dex, which, in the context of GR, pro-
emission curves were multiplied by the ratio of control CFP signal duces predominantly nuclear aggregation. Test compounds were
to sample CFP signal in the window 482–492 nm, following 435 added to the culture medium in quadruplicate wells at the time of
nm excitation: NCFP  CFPcontrol/CFPsample. After such normalization, replating, and cells were assayed after 48 hr in culture. The following
subtraction of the CFP control curve from the sample curve removes list of compounds was screened at the concentrations indicated,
the contribution of CFP bleedthrough from the sample FRET scan. which were, where possible, approximately 2.5-, 5-, and 10-fold
To adjust for YFP crossover activation, a control sample transfected over the reported Ki or EC50 for each. Compound (major target:
with YFP alone was used. The control YFP control signal (em 520– conc1; conc2; conc3), Chelerythrine (Protein Kinase C: 2 M; 8 M;
530 nm) from 435 nm excitation was divided by the YFP control 40 M), KT5823 (Protein Kinase G: 0.5 M; 10 M; 2 M), PD98659
signal following 485 nm excitation to determine the following cross- (MEK: 5M; 19M; 95M), 4-Cyano-3-methyl-Isoquinoline (Protein
over activation ratio: XYFP (YFPex435/em520–530/YFPex485/em520–530). With this Kinase A: 0.1 M; 0.4 M; 2 M), KN62 (Cam Kinase II: 40 M; 8
information, it is possible to subtract out the contribution of YFP M; 2 M), Y-27632 (ROCK I & II: 0.5 M; 2 M; 10 M), PP2 (Src
crossover activation to the FRET signal. The resulting curve contains Kinases: 0.013 M; 0.05 M; 0.25 M), ZM336372 (C-RAF: 0.17 M;
emission solely due to FRET: FRETcalc  [NCFP 	 (Sampleex435)]  0.67 M; 3.33 M), SB202190 (P38 MAP Kinase: 0.75 M; 3 M; 15
(CFP controlex435)  [NCFP 	 (Sampleex485) 	 XYFP]. M), ML-9 (Myosin Light Chain Kinase: 0.01 M; 0.04 M; 0.2 M),
LY294002 (PI3 kinase: 5.0M; 20M; 100M), MG132 (Proteasome:
0.01 M; 0.04 M; 0.2 M), TSA (Histone Deacetylase: 5 ng/ml),FRET Measurements Using Fixed
SAHA (Histone Deacetylase: 0.05 M), Na-4-phenylbutyrate (His-Excitation/Emission Windows
tone Deacetylase: 5 mM; 20 mM; 100 mM), Na-butyrate (HistoneAutomated measurements of each well were taken on the FPR using
Deacetylase: 5 mM; 20 mM; 100 mM), and Geldanomycin (hsp90:the following three windows: CFP ex 435  2.5 nm/em 485  6 nm;
0.1 g/ml; 0.4 g/ml; 2 g/ml).FRET ex 435  2.5 nm/em 485  6 nm; YFP ex 485  2.5 nm/em
530 6 nm. Data were analyzed as follows. All readings were back-
ground subtracted based on averaged readings from cells trans- High-Throughput Screen of the Annotated
fected with vector alone. Controls containing CFP alone were used Compound Library
to normalize sample readings in all three windows by the ratio of The ACL consisted of a collection of2800 biologically active small
control-to-sample signal in the CFP window: NCFPCFPcontrol/CFPsample. molecules (a gift from B. Stockwell). Daughter plates were created
After this normalization, subtraction of CFP control signal in the in duplicate containing the compounds at a concentration of 80
FRET window from sample signal in the FRET window removes the g/ml from the stock 4 mg/ml 384-well microtiter plates using a
contribution of CFP bleedthrough from the sample signal. Control Zymark SciClone ALH. Compounds were aliquoted in 96-well plates
samples containing YFP alone were used to characterize YFP cross- (Costar 3603) at a concentration of 4 g/ml, at which most of the
over excitation as a percentage of signal in the YFP window that compounds are active but are not toxic to the cells. To screen the
appeared the FRET window: XYFP  YFPFRET/YFPYFP. Subtraction of library, HEK293 cells stably expressing RFP were plated in 10 cm
this percentage of the sample signal in the YFP window from the plates to obtain 80% confluence on the day of transfection. Each
sample signal in the FRET window removes the contribution of plate was transfected with 2 g of ARN127(65)CFP/YFP each, and
crossover excitation from the sample FRET signal. The remaining 0.7 g p6RGR using 50 l Plus reagent and 76 l Lipofectamine
signal is due solely to FRET. FRETcalc  (NCFP 	 Sample435/530) (Pure according to manufacturer’s protocol (Invitrogen). After 3 hr, com-
CFP435/530)  [(NCFP  (Sample485/530) 	 XYFP]. plete medium was added and the plates were incubated further for
3 hr. Next, after adding 100 nM dex, the cells were counted and
plated at a density of 70,000 cells/well in duplicate 96-well daughterDetergent Fractionation
plates containing single aliquots of compounds from the library. TheTo measure effects of GR and GR, HEK293 cells were cultured in
cells were then cultured for 48 hr to allow aggregate formation.3.5 cm wells and transfected with 1 g of total DNA consisting of
After fixing the cells, FRET signal was measured according to meth-0.5 g of ARN127(Q25/65)YFP and 0.5 g of p6RGR or p6RGR.
ods described above. Several internal controls were used to stan-Cells were cultured in the presence or absence of 100 nM dexameth-
dardize each experiment. Mock-transfected cells were used to con-asone for 48 hr. For titration of Y-27632, cells were transfected with
trol for background autofluorescence and light scattering. To controlARN127(65)CFP/YFP alone and cultured with the indicated amounts
for CFP bleedthrough and crossover excitation of YFP, additionalof drug. Cells were harvested by washing off the plate in PBS/5 mM
wells contained cells expressing ARN127(25)CFP or ARN127(25)YFPEDTA, gentle centrifugation, and freezing of the pellets. Cell pellets
alone. RFP was measured to control for nonspecific effects onwere stored at 20C until future use. At this time, ice-cold lysis
steady-state protein levels. ARN127(25)CFP/YFP expression servedbuffer was prepared consisting of PBS with 1% Triton X-100 (Sigma)
as a reference point for background FRET levels without aggregationand 1 g/ml each of aprotinin, leupeptin, and pepstatin (Sigma).
(a theoretical maximum effect on aggregation inhibition). FRET mea-Pellets were resuspended in 400 l of lysis buffer, and lysis was
surements for each experiment were thus scaled between 100%performed by 10–15 passages through a 26 gauge needle to break
(cells with no drug treatment) and 0% (FRET levels from unexpandedup nuclei and shear chromatin. The lysate was centrifuged at
protein). Last, each plate also contained wells treated with Y-2763215,000 	 g for 5 min at 4C. 100 l of the supernatant was removed
(50 M) as a positive control.and the remainder discarded. The pellet was then washed 1	 with
lysis buffer and again centrifuged at 15,000	 g. The pellet was then
resuspended in 50 l of SDS sample buffer and boiled for 10 min. Assay of Y-27632 on Neurodegeneration in Drosophila
Transgenic flies were used, harboring a human huntingtin exon 1Total protein was determined in each supernatant fraction according
to the Bradford method, and fractions representing equivalent fragment with 93 glutamines (htt exon 1(Q93)) that is expressed in
all fly neurons under the control of the elav:Gal4 driver. Flies wereamounts of total protein were diluted into SDS sample buffer. Equiv-
alent proportions of the pellet fractions were also diluted into SDS treated by maintaining adults on food containing 25 M Y-27632 or
no drug supplement. Flies expressing the transgene display pro-sample buffer, and samples were resolved by electrophoresis on a
10% polyacrylamide gel. After transfer to a nylon membrane, immu- gressive degeneration of the photoreceptor neurons, which is re-
vealed by a time-dependent decrease in the number of rhabdomeresnoblotting was performed using rabbit N-20 anti-AR antibody at
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per ommatidium (Steffan et al., 2001). Normal fly eyes have seven Georgalis, Y., Starikov, E.B., Hollenbach, B., Lurz, R., Scherzinger,
E., Saenger, W., Lehrach, H., and Wanker, E.E. (1998). Huntingtinvisible rhabdomeres, while flies expressing htt exon1 (Q93) display
reduced numbers of rhabdomeres. The number of rhabdomeres in aggregation monitored by dynamic light scattering. Proc. Natl. Acad.
Sci. USA 95, 6118–6121.treated versus untreated flies were analyzed 7 days posteclosion
by the pseudopupil technique as described (Steffan et al., 2001). Hirose, M., Ishizaki, T., Watanabe, N., Uehata, M., Kranenburg, O.,
Approximately 50–60 ommatidia were analyzed for rhabdomere con- Moolenaar, W.H., Matsumura, F., Maekawa, M., Bito, H., and Naru-
tent on each of 10–12 flies from each treatment group, and the miya, S. (1998). Molecular dissection of the Rho-associated protein
average number of rhabdomeres per ommatidium in each individual kinase (p160ROCK)-regulated neurite remodeling in neuroblastoma
was determined. Percent rhabdomere loss was calculated as 100	 N1E–115 cells. J. Cell Biol. 141, 1625–1636.
((7  average number remaining)/7) before and after treatment.
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